Cancer
Cancer Market Research, Intelligence and Forescasts
In this section you will find information products, including market research, covering Cancer research, including latest technologies, company profiles, biopharmaceuticals, market data and information covering Europe, the UK, North America and Asia.Stay up-to-date with new products added to this category »
| Title | Publication Date | Price |
|---|---|---|
|
Targeting Cancer Stem Cells Emerging Therapeutic, Therapeutic Strategies and Pipeline Developments (2010) |
January 2010 | £1599 |
|
Lung Cancer Drug Pipeline Update 2010 |
January 2010 | £1345 |
|
Liver Cancer Drug Pipeline Update 2010 |
January 2010 | £895 |
|
Ovarian Cancer Drug Pipeline Update 2010 |
January 2010 | £1345 |
|
Hematological Cancers Drug Pipeline Update 2010 |
January 2010 | £1795 |
|
Pancreatic Cancer Drug Pipeline Update 2010 |
January 2010 | £1345 |
|
Renal Cancer Drug Pipeline Update 2010 |
January 2010 | £1345 |
|
Analytical Tool: Current & Future Lung Cancer Therapeutics |
January 2010 | £2780 |
|
Colorectal Cancer Drug Pipeline Update 2010 |
January 2010 | £1345 |
|
Analytical Tool: The Commercial Success of Cancer Therapeutic Antibodies |
January 2010 | £3590 |
|
Prostate Cancer - A Therapeutic & Competitive Insight Pipeline Update 2010 |
January 2010 | £1345 |
|
Bladder Cancer Drug Pipeline Update 2010 |
January 2010 | £895 |
|
Analytical Tool – Hematological Cancers |
January 2010 | £5340 |
|
Head and Neck Cancer Drug Pipeline Update 2010 |
January 2010 | £1345 |
|
Cancer Vaccines Drug Pipeline Update 2010 |
January 2010 | £1345 |
|
Analytical Tool: Competitive Outlook on Cancer Vaccines |
January 2010 | £2780 |
|
Colorectal Cancer Drug Pipeline Analysis and Market Forecasts to 2016 |
January 2010 | £1305 |
|
The Cancer Market Outlook To 2014 Competitive landscape, market size, pipeline analysis and growth opportunities |
January 2010 | £3835 |
|
Analytical Tool: Breast Cancer R&D Comprehensive Guide |
January 2010 | £2780 |
|
Analytical Tool: Analysis of Cancer Immunotherapy The World Guide |
January 2010 | £4440 |
|
Analytical Tool: Prostate Cancer A Therapeutic & Competitive Insight |
January 2010 | £2780 |
|
Ovarian Cancer Drug Pipeline Analysis and Market Forecasts to 2016 |
January 2010 | £1305 |
|
Breast Cancer Drug Pipeline Update 2010 |
January 2010 | £1345 |
|
Renal Cancer Drug Pipeline Analysis and Market Forecasts to 2016 |
January 2010 | £1305 |
|
Global Peritoneal Dialysis Market Strategic Analysis and Opportunity Assessment |
January 2010 | £2285 |
|
Prostate Cancer Drug Pipeline Analysis and Market Forecasts to 2015 |
January 2010 | £1305 |
|
Head and Neck Cancer Drug Pipeline Analysis and Market Forecasts to 2016 |
January 2010 | £1305 |
|
Bladder Cancer Drug Pipeline Analysis and Market Forecasts to 2016 |
January 2010 | £1305 |
|
Acute Myeloid Leukemia Drug Pipeline Analysis and Market Forecasts to 2016 |
January 2010 | £1305 |
|
Breast Cancer Drug Pipeline Analysis and Market Forecasts to 2016 |
January 2010 | £1305 |
|
Brain Cancer Drug Pipeline Update 2010 |
January 2010 | £1345 |
|
Cervical Cancer Drug Pipeline Analysis and Market Forecasts to 2016 |
January 2010 | £1305 |
|
Cancer Vaccines Pipeline Analysis and Market Forecasts to 2016 |
January 2010 | £1305 |
|
Analytical Tool - Colorectal Cancer |
January 2010 | £2780 |
|
Non-Small-Cell Lung Cancer (NSCLC) Drug Pipeline Analysis and Market Forecasts to 2015 |
December 2009 | £1305 |
|
Lung Cancer Therapeutics Market Outlook and Pipeline Analysis |
November 2009 | £975 |
|
Cancer Therapies Global Market Opportunities |
November 2009 | £1955 |
|
Prostate Cancer Therapeutics A Global Market Perspective |
November 2009 | £1955 |
|
CXCR and CXCL Agonists and Antagonists Competitor Analysis |
November 2009 | £270 |
|
Monoclonal Antibody Based Products Global Trends |
November 2009 | £1955 |
|
Competitor Analysis: EGF-R Agonists and Antagonists |
October 2009 | £270 |
|
Pipeline Insight: Colorectal Cancer Growing trend towards personalized medicine |
October 2009 | £7445 |
|
Chinese Markets for Colon Cancer Treatment Drugs |
September 2009 | £2610 |
|
Competitor Analysis: Her2 Receptor Antagonists |
September 2009 | £225 |
|
Chinese Markets for Brain Cancer Treatment Drugs |
September 2009 | £2610 |
|
Chinese Markets for Cervical Cancer Treatment Drugs |
September 2009 | £2610 |
|
Chinese Markets for Bladder Cancer Treatment Drugs |
September 2009 | £2610 |
|
Cancer Diagnostic Testing Instrumentation Operating Characteristics, Features and Selling Prices of Leading Automated and Semiautomated Analyzers |
September 2009 | £325 |
|
Cancer Diagnostic Technologies Assessment of Current and Emerging Technologies, and Their Potential Market Applications |
September 2009 | £1110 |
|
Cancer Diagnostic Testing A Global Market Overview - Facilities, Test Volumes, and Sales Forecasts by Country |
September 2009 | £425 |
|
The UK Cancer Diagnostics Market |
September 2009 | £2675 |
|
Cancer Diagnostics Market New Product Development Opportunities, Market Penetration Strategies, Entry Barriers and Risks |
September 2009 | £325 |
|
The Spanish Cancer Diagnostics Market |
September 2009 | £2675 |
|
The US Cancer Diagnostics Market |
September 2009 | £4830 |
|
The Italian Cancer Diagnostics Market |
September 2009 | £2675 |
|
The Japanese Cancer Diagnostics Market |
September 2009 | £3720 |
|
The German Cancer Diagnostics Market |
September 2009 | £2675 |
|
Leading Cancer Diagnostics Market Players Strategic Assessments of Major Suppliers and Emerging Market Entrants |
September 2009 | £1435 |
|
Current and Emerging Cancer Diagnostic Tests Emerging Assays and Companies Developing New Technologies and Products |
September 2009 | £1860 |
|
The French Cancer Diagnostics Market |
September 2009 | £2675 |
|
Competitive Outlook of Cancer Drug Development The Missing Handbook to New Product Planning and Portfolio Planning |
August 2009 | £2200 |
|
CHK and KSP/Eg5 Inhibitors Competitor Analysis |
August 2009 | £155 |
|
PI3K-Akt-mTOR Pathway Inhibitors Competitor Analysis |
July 2009 | £450 |
|
Bcr-Abl Kinase Inhibitors Competitor Analysis |
July 2009 | £180 |
|
Immunotoxins Competitor Analysis |
July 2009 | £135 |
|
HDAC Inhibitors Competitor Analysis |
July 2009 | £360 |
|
IGF-1R Antagonists Competitor Analysis |
July 2009 | £225 |
|
Antibody-Drug Conjugates (ADC) Competitor Analysis |
June 2009 | £225 |
|
Immunocytokines Competitor Analysis |
June 2009 | £135 |
|
Aurora Kinase Inhibitors Competitor Analysis |
June 2009 | £155 |
|
MEK Inhibitors Competitor Analysis |
June 2009 | £135 |
|
Therapeutic Peptides in Oncology Favorable Conditions But Where to Commercialize? |
May 2009 | £3095 |
|
Plk-1 Inhibitors Competitor Analysis |
May 2009 | £90 |
|
Raf Inhibitors Competitor Analysis |
May 2009 | £180 |
|
World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The |
May 2009 | £2610 |
|
Novel Mitotic Kinase Inhibitors Competitor Analysis |
May 2009 | £315 |
|
Ras-Raf-MEK-ERK Inhibitors Competitor Analysis |
May 2009 | £315 |
|
PARP Inhibitors Competitor Analysis |
April 2009 | £90 |
|
Leukemia A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking |
April 2009 | £1750 |
|
Hypoxia-Inducible Factor (HIF) Competitor Analysis |
April 2009 | £90 |
|
CD3 Antagonists Competitor Analysis |
March 2009 | £180 |
|
Cancer Market Trends 2008 - 2012 Key market forecasts and growth opportunities |
January 2009 | £1100 |
|
Breast Cancer Drug Pipeline Update 2009 |
January 2009 | £1345 |
|
Lung Cancer Drug Pipeline Update 2009 |
January 2009 | £1345 |
|
Protein Kinase C (PKC) Inhibitors Competitor Analysis |
January 2009 | £180 |
|
CD20 Antibodies Competitor Analysis |
January 2009 | £180 |
|
Analytical Tool - Cancer Therapeutic Antibodies |
January 2009 | £3680 |
|
Analytical Tool - Melanoma |
January 2009 | £2780 |
|
Leukemia Drug Pipeline Update 2009 |
January 2009 | £1345 |
|
Hematological Cancers Drug Pipeline Update 2009 |
January 2009 | £1795 |
|
Lymphoma Drug Pipeline Update 2009 |
January 2009 | £1345 |
|
Analytical Tool - Breast Cancer |
January 2009 | £2780 |
|
Liver Cancer Drug Pipeline Update 2009 |
January 2009 | £895 |
|
Analytical Tool - Angiogenesis in Oncology |
January 2009 | £2780 |
|
Analytical Tool - Apoptosis in Oncology |
January 2009 | £2780 |
|
Stakeholder Opinions: Cancer Cachexia Higher profile needed to unlock market potential of neglected syndrome |
January 2009 | £1305 |
|
Pancreatic Cancer Drug Pipeline Update 2009 |
January 2009 | £1345 |
|
Analytical Tool - Cancer Vaccines |
January 2009 | £2780 |
|
Ovarian Cancer Drug Pipeline Update 2009 |
January 2009 | £1345 |
|
Colorectal Cancer Drug Pipeline Update 2009 |
January 2009 | £1345 |
|
Analytical Tool - Protein Kinase Inhibitors in Oncology |
January 2009 | £2780 |
|
Cancer Vaccines Drug Pipeline Update 2009 |
January 2009 | £1345 |
|
Angiogenesis in Oncology Drug Pipeline Update 2009 |
January 2009 | £1345 |
|
Melanoma Drug Pipeline Update 2009 |
January 2009 | £1345 |
|
Analytical Tool - Prostate Cancer A Therapeutic & Competitive Insight |
January 2009 | £2780 |
|
Brain Cancer Drug Pipeline Update 2009 |
January 2009 | £1345 |
|
Bladder Cancer Drug Pipeline Update 2009 |
January 2009 | £895 |
|
China Anti-Cancer Drug Market Report The Chinese Hospital Cancer Drug Utilization |
December 2008 | £5225 |
|
MarketWatch: Cancer |
November 2008 | £69 |
|
Pipeline Insight: Molecular Targeted Cancer Therapies More pipeline activity, less product differentiation |
November 2008 | £5225 |
|
Stakeholder Insight: Chronic Leukemias Is there room left for improvement? |
November 2008 | £5225 |
|
Cancer Drug Resistance 2008 |
September 2008 | £1675 |
|
Currently Druggable in Prostate Cancer A Drug Target Competitive Analysis |
September 2008 | £1750 |
|
Global Cancer Treatment Forecast to 2012 |
August 2008 | £1045 |
|
Currently Druggable in Breast Cancer A Drug Target Competitive Analysis |
August 2008 | £1750 |
|
Cancer Therapeutics Market Insight and R&D Pipeline Analysis |
August 2008 | £2285 |
|
Cancer Biomarkers: Adoption Is Driving Growth |
July 2008 | £2450 |
|
Cytology and HPV Testing World Markets |
July 2008 | £2220 |
|
Cancer Personalized Medicine 2008 |
July 2008 | £2425 |
|
Cancer Antibodies Competitive Positioning for Success |
June 2008 | £1750 |
|
Cancer Antibodies: Competitive Positioning for Success |
June 2008 | £1750 |
|
Cancer Vaccines: Aim and Shoot |
May 2008 | £1750 |
|
Cancer Therapeutics Markets |
May 2008 | £2220 |
|
Cancer Diagnostic Testing World Markets |
April 2008 | £2220 |
|
Companion Diagnostics in Personalized Medicine and Cancer Therapy |
April 2008 | £2220 |
|
Cancer Cell Therapy Markets |
March 2008 | £2220 |
|
Cardiac Toxicity |
March 2008 | £1495 |
|
The Worldwide Market for Cancer Diagnostics 3rd Edition |
March 2008 | £2610 |
|
Treatment Methods for Early and Advanced Prostate Cancer |
March 2008 | £99 |
|
Textbook of Lung Cancer |
March 2008 | £115 |
|
ESMO Handbook of Cancer Prevention European Society for Medical Oncology Handbooks |
February 2008 | £22.5 |
|
Cancer Therapies: Technologies and Global Markets |
January 2008 | £3165 |
|
Reflectance Confocal Microscopy of Cutaneous Tumors An Atlas with Clinical, Dermoscopic and Histological Correlations |
January 2008 | £129.95 |
|
The Cancer Market Outlook to 2012 |
January 2008 | £1995 |
|
Stakeholder Opinions: Head and Neck Cancer Innovatives to Change the Face of Treatment |
November 2007 | £1310 |
|
Who's Developing What in New Cancer Drugs 2006? |
November 2007 | £495 |
|
The Drug Target Atlas of Protein Kinase Inhibitors in Oncology |
November 2007 | £1760 |
|
Pipeline Insight Therapeutic Cancer Vaccines A turbulent path from bench to bedside |
October 2007 | £1955 |
|
Pipeline Insight: Molecular Targeted Cancer Therapies Can anything else revolutionize the market? - Cancer |
October 2007 | £4960 |
|
Multiple Myeloma |
October 2007 | £105 |
|
Pipeline Insight: Cancer Overview Increasing Diversity Offers Both High Risk And Reward |
September 2007 | £4960 |
|
Cancer Vaccine Developments to 2011 |
September 2007 | £1296 |
|
Hereditary Breast Cancer |
September 2007 | £105 |
|
Prognostic and Predictive Factors in Gynecologic Cancers |
September 2007 | £55 |
|
Neurological Complications of Systemic Cancer |
September 2007 | £115 |
|
Image-Guided Radiotherapy of Lung Cancer |
August 2007 | £130 |
|
Skull Based Tumors |
August 2007 | £230 |
|
Cancer-Associated Thrombosis |
August 2007 | £115 |
|
Melanoma - Targeted Therapeutics |
July 2007 | £1400 |
|
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Melanoma and NSCLC |
July 2007 | £2475 |
|
Commercial Insight: Top 20 Cancer Therapy Brands Sales of targeted therapies overtake cytotoxics in 2006 |
July 2007 | £4960 |
|
Stakeholder Opinions: Primary Brain Cancer Temozolomide Turns Heads |
July 2007 | £1305 |
|
Clinical Pathology of Urological Tumours |
July 2007 | £125 |
|
Innovative And Targeted Cancer Therapies Key Technologies, New Applications And Leading Players |
July 2007 | £1495 |
|
China Anti-tumor Drugs Market Report 2007 |
June 2007 | £195 |
|
Antibody Drug Target Atlas in Oncology |
June 2007 | £1760 |
|
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Breast- and Prostate Cancer |
June 2007 | £2475 |
|
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Leukemias and Lymphomas |
June 2007 | £2475 |
|
Protein Kinase Inhibitors in Oncology Drug Pipeline Update 2009 |
May 2007 | £1345 |
|
Renal Cancer Drug Pipeline Update 2009 |
May 2007 | £1345 |
|
Analytical Tool - Analysis of Cancer Immunotherapy The World Guide |
May 2007 | £4440 |
|
Analytical Tool - Current & Future Lung Cancer Therapeutics |
May 2007 | £2780 |
|
Analytical Tool - Lymphoma Therapeutics & Competitive Insights |
May 2007 | £2780 |
|
Analytical Tool - Hematological Cancers |
May 2007 | £5340 |
|
Prostate Cancer Drug Pipeline Update 2009 |
May 2007 | £1345 |
|
Lung Cancer Translational and Emerging Therapies |
May 2007 | £100 |
|
Targeted Therapeutics in Non-Small Cell Lung Cancer |
April 2007 | £1400 |
|
Non-Small Cell Lung Cancer Drug Pipeline Update 2007 |
April 2007 | £1345 |
|
Global Cancer Focus Company Directory |
April 2007 | £1400 |
|
Stakeholder Opinions: Small Cell Lung Cancer and Malignant Mesothelioma Limited R&D activity provides opportunity for early-phase pipeline drugs |
March 2007 | £1310 |
|
Immunotherapy of Cancer |
March 2007 | £3165 |
|
Breast Cancer - Therapeutic And Competitive Insights |
February 2007 | £1400 |
|
Breast Cancer Therapeutic And Competitive Insights |
February 2007 | £1400 |
|
Innovations in Cancer Novel Therapeutics, New Diagnostics and Future R&D Strategies |
February 2007 | £1495 |
|
Cancer Therapeutics: The Worldwide Market The Worldwide Market , 2nd Editon |
February 2007 | £2610 |
|
World market for cancer vaccines 2007-2012 |
January 2007 | £1999 |
|
Top 7 Cancer Indications Therapeutic & Competitive Insights |
January 2007 | £6235 |
|
Stakeholder Opinions: Melanoma Lucrative commercial opportunities persist |
December 2006 | £1305 |
|
Pipeline Insight: Therapeutic Cancer Vaccines A turbulent path from bench to bedside |
December 2006 | £3915 |
|
Targeted Therapies in Oncology A World Review |
December 2006 | £4440 |
|
Stakeholder Opinions: Gynecological Cancers Niche opportunities in advanced disease |
December 2006 | £1310 |
|
Stakeholder Insight: Pricing and Reimbursement in Oncology Do payers believe oncology drugs offer good value? |
December 2006 | £3915 |
|
Competitive Outlook on Apoptosis in Oncology |
December 2006 | £1750 |
|
Triple Analysis: Apoptosis Agents, Protein Kinase Inhibitors and Anti-Angiogenic Agents in Oncology |
December 2006 | £4645 |
|
Preclinical Cancer Therapeutics 2007 Decoding Next Generation Drug Targets for Market Success |
December 2006 | £1600 |
|
Stakeholder Insight: Non-Small Cell Lung Cancer The need for greater product differentiation in an increasingly crowded market |
November 2006 | £5225 |
|
Regulator Perceptions in Cancer Evolving opinions about the oncology drug approval process |
November 2006 | £655 |
|
Emerging Cancer Vaccine Market, The 2nd Edition |
November 2006 | £2285 |
|
Hematological Cancers - A Therapeutic & Competitive Insight |
October 2006 | £2650 |
|
Colorectal Cancer: Pipeline/Commercial Insight Shaping the future dynamics of colorectal cancer management |
October 2006 | £5225 |
|
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies More drugs on the market, more targets in the pipeline |
October 2006 | £5225 |
|
Competitive Outlook on Antiangiogenesis and Vascular Targeting in Oncology |
October 2006 | £1750 |
|
Triple Analysis: Non Small Cell Lung Cancer, Protein Kinase Inhibitors & Anti-Angiogenic Agents |
October 2006 | £3095 |
|
Stakeholder Insight: Supportive Care in Cancer Treatment Some first-generation products proving difficult to dislodge |
October 2006 | £5225 |
|
Leukemia - A Therapeutic & Competitive Insight |
October 2006 | £1750 |
|
Emerging Opportunities in Cancer Nanomedicine |
August 2006 | £995 |
|
Triple Analysis: Protein Kinase Inhibitors, Antibodies and Vaccines in Oncology |
August 2006 | £3095 |
|
Triple Analysis: Melanoma Therapeutics, Antibodies and Vaccines in Oncology |
August 2006 | £3095 |
|
Competitive Outlook on Non-Antibody Based Cancer Vaccines |
August 2006 | £1750 |
|
What's Hot in Cancer Drug R&D? |
July 2006 | £295 |
|
Commercial Insight Top 20 Cancer Therapeutics |
July 2006 | £5675 |
|
Stakeholder Opinions: Ovarian Cancer Growing importance as secondary indication for targeted therapies |
July 2006 | £1435 |
|
Cancer Biomarkers Enhancing diagnostic, therapeutic and developmental strategies |
May 2006 | £1435 |
|
Chemotherapy Market Insights, 2006-2016 A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities |
April 2006 | £1900 |
|
Stakeholder Opinions: Gastric Cancer Targeted Therapies Home In On a Neglected Tumor Type |
March 2006 | £1435 |
|
Triple Progress Analysis: Melanoma, Colorectal & Lung Cancer |
March 2006 | £3095 |
|
Current and Future Therapies for Lung Cancer A Therapeutic & Competitive Insight |
March 2006 | £1750 |
|
Liver Cancer: Industry Background Report List of Companies |
October 2005 | £235 |
|
Pancreatic Cancer: Industry Background Report List of Companies |
October 2005 | £235 |
|
Lung cancer: Industry Background Report List of Companies |
October 2005 | £295 |
|
Breast Cancer: Industry Background Report List of Companies |
October 2005 | £345 |
|
Colorectal Cancer: Industry Background Report List of Companies |
October 2005 | £295 |
|
Prostate Cancer: Industry Background Report List of Companies |
October 2005 | £345 |
|
Apoptosis: Industry Background Report List of Companies |
October 2005 | £345 |
|
Analytical Tool: Competitive Outlook on HCV |
July 2004 | £1345 |
